Spinocerebellar Ataxia Type 31 (SCA31): Disease Characteristics Report

Executive summary

Spinocerebellar ataxia type 31 (SCA31) is a rare, late-onset, slowly progressive, autosomal-dominant cerebellar neurodegenerative disorder caused by a complex pentanucleotide-repeat insertion at chromosome 16q22.1 in an intronic region shared by BEAN1 and TK2. The disease-associated element is approximately 2.5–3.8 kb and contains (TGGAA)n, (TAGAA)n, (TAAAA)n, and (TAAAATAGAA)n; among these, (TGGAA)n is the motif consistently associated with pathogenicity. SCA31 has a pronounced Japanese founder effect and is essentially absent from most non-Japanese populations. Clinically, it is usually a relatively “pure” cerebellar syndrome beginning near 60 years of age, with gait/truncal and limb ataxia and dysarthria. Human pathology and experimental data support toxic gain-of-function by brain-expressed (UGGAA)n RNA, nuclear RNA foci, altered RNA-binding-protein homeostasis, repeat-associated translation of poly-WNGME pentapeptide protein, and selective Purkinje-cell injury. No disease-modifying treatment has been established; current care is supportive, while toxic-RNA-binding compounds and manipulation of RNA chaperones remain preclinical concepts. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 7-9)

The following table provides a compact knowledge-base representation.

Table: This table condenses the highest-confidence, knowledge-base-ready facts on Spinocerebellar Ataxia Type 31, including its causal repeat expansion, core phenotype, mechanistic evidence, diagnostics, and model systems. It also flags domains where the current evidence is limited or not established.

1. Disease information

Definition and classification

SCA31 is a Mendelian autosomal-dominant repeat-expansion disorder and neurodegenerative cerebellar ataxia. Its cardinal manifestation is progressive cerebellar ataxia, generally without the prominent brainstem, pyramidal, peripheral-neuropathic, cognitive, or systemic manifestations found in many multisystem SCAs. The source material summarized here is principally aggregated disease-level evidence from pedigrees, clinical cohorts, human postmortem tissue, and experimental models—not individual EHR records. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 5-7)

Identifiers and synonyms

• MONDO: MONDO:0007296.
• Principal names: spinocerebellar ataxia type 31; spinocerebellar ataxia 31; SCA31.
• Historical/locus terminology: chromosome 16q22.1-linked autosomal-dominant cerebellar ataxia; the phenotype was historically associated with “16q-ADCA.”
• Disease-associated targets: Open Targets links SCA31 to BEAN1 (Ensembl ENSG00000166546) and, with substantially weaker association evidence, TK2 (ENSG00000166548). The underlying literature records include PMIDs 17611710, 19878914, 22992774, 20301317, and 35084690. (OpenTargets Search: spinocerebellar ataxia type 31-BEAN1,TK2)
• OMIM/Orphanet/MeSH and dedicated ICD codes: not reliably established in the retrieved evidence. General coding systems may classify the condition under hereditary ataxia or spinocerebellar ataxia rather than a unique SCA31 code; these mappings should be verified directly against current releases before database ingestion.

A concise statement from the November 2023 disease review is: “Spinocerebellar ataxia type 31 (SCA31) is one of the most common forms of autosomal-dominant cerebellar ataxia in Japan.” DOI: 10.1038/s10038-022-01091-4. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2023spinocerebellarataxiatype pages 1-2)

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factor

The causal lesion is a germline, heterozygous, complex intronic pentanucleotide-repeat expansion at 16q22.1. It lies in an intron shared by oppositely transcribed BEAN1 and TK2. Disease alleles are approximately 2.5–3.8 kb and contain several repeat motifs, but (TGGAA)n is the sequence that segregates with SCA31 and was not observed on control chromosomes in the foundational comparisons. Short (TAAAA)8–20 alleles are common in unaffected Japanese controls. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2)

Risk factors

• Genetic: inheritance of the disease-associated (TGGAA)n-containing expansion is the primary risk factor. Longer insertion length correlates inversely with age at onset, although repeat composition and technical measurement complexity limit simple repeat-count prediction. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 7-9)
• Family history: an affected first-degree relative is a major clinical risk indicator under autosomal-dominant inheritance.
• Population ancestry: Japanese ancestry substantially raises prior probability because of a strong founder effect. Cases outside Japan have notably included people of Japanese descent, including Brazilian families. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 5-7)
• Age: age is not an etiologic exposure, but clinical penetrance is strongly age-dependent because onset is usually in late adulthood.
• Sex: no reproducible sex-specific risk or sex-ratio difference was established in the retrieved studies.
• Modifier genes: TDP-43/TARDBP, FUS, and HNRNPA2B1 modify toxicity experimentally, but they are not established human genetic modifier loci. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 9-11)

Environmental and protective factors

No validated toxin, infection, diet, smoking pattern, alcohol exposure, occupational factor, medication, or other environmental exposure has been shown to cause or specifically modify SCA31. No protective human allele, dietary intervention, or lifestyle factor has been validated. Consequently, a specific SCA31 gene–environment interaction is not established. General avoidance of alcohol excess and cerebellotoxic medications may reduce superimposed ataxia but does not prevent the inherited disease.

3. Phenotypes

Core phenotype

Mean reported onset ranges from 58.5 ± 10.3 years to 63.8 years, making SCA31 one of the latest-onset SCAs. The course is chronic and progressive rather than episodic, relapsing, or remitting. Available reports do not supply robust percentage frequencies for every symptom; ataxia and dysarthria are core, whereas parkinsonism and blepharospasm are occasional. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 5-7)

Functional and quality-of-life effects

Progressive gait and balance impairment affect community mobility, falls risk, driving, self-care, and ultimately independent ambulation. Dysarthria impairs communication, while limb incoordination affects feeding, writing, dressing, and other fine-motor tasks. Wheelchair dependence was reported at a mean age of 79.4 ± 1.7 years. No SCA31-specific EQ-5D, SF-36, PROMIS, or validated disease-specific quality-of-life estimates were identified. SARA is the principal quantitative neurological severity scale reported. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 5-7)

4. Genetic and molecular information

Genes and variant class

• BEAN1—brain expressed associated with NEDD4 1; principal disease-linked gene/locus in Open Targets.
• TK2—thymidine kinase 2; shares the affected intronic interval and is transcribed in the opposite direction. This SCA31 mechanism is distinct from recessive coding-variant TK2 deficiency.
• Variant type: complex intronic tandem-repeat insertion/expansion; germline; heterozygous.
• Functional class: toxic gain of function at the RNA level, with an additional toxic repeat-associated translation product; not a conventional BEAN1 or TK2 coding loss-of-function allele. (OpenTargets Search: spinocerebellar ataxia type 31-BEAN1,TK2, ishikawa2023spinocerebellarataxiatype pages 2-3, zhang2022mechanisticandtherapeutic pages 7-9)

The repeat is bidirectionally transcribed. BEAN1 produces brain-specific (UGGAA)n-containing RNA, whereas the opposite TK2 direction produces (UUCCA)n RNA more broadly. The clinical and pathological restriction to the nervous system, together with BEAN1’s brain-restricted expression, supports the (UGGAA)n transcript as the dominant pathogenic species. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2023spinocerebellarataxiatype pages 1-2)

Classification, frequency, and structural features

The canonical expansion is pathogenic by segregation, population specificity, human pathology, and functional-model evidence. Conventional SNV-focused ACMG/AMP criteria are not sufficient by themselves for this complex repeat; laboratories should use repeat-expansion-specific validation and locus expertise. Approximately 99.7% of controls in one summary carried short (TAAAA)8–20 repeats, and control insertions lacking TGGAA were rare (approximately 0.23%). Standard gnomAD SNV allele-frequency fields are not an adequate representation of this lesion. (zhang2022mechanisticandtherapeutic pages 7-9, ishikawa2023spinocerebellarataxiatype pages 2-3)

No established large deletion, translocation, inversion, aneuploidy, somatic mosaic mechanism, DNA-methylation signature, or chromatin biomarker specific to SCA31 was found. Somatic repeat instability is biologically plausible for repeat diseases but was not established as a clinical driver in the retrieved SCA31 evidence.

5. Environmental information

SCA31 is not infectious, zoonotic, toxic, radiation-induced, or lifestyle-caused. No infectious agent or environmental trigger is implicated. Alcohol, sedatives, anticonvulsants, and other cerebellar-toxic exposures can worsen balance nonspecifically and should be reviewed clinically, but they are not SCA31 causes. CTD-style disease–chemical causal relationships and SCA31-specific lifestyle-effect estimates were not identified.

6. Mechanism and pathophysiology

Ordered causal chain

1. A germline (TGGAA)n-containing complex repeat expansion in the shared BEAN1/TK2 intron leads to bidirectional transcription of expanded noncoding repeat RNA at 16q22.1. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2019molecularmechanismsand pages 1-3)
2. Brain-specific BEAN1 transcription results in expanded (UGGAA)n RNA in cerebellar neurons, especially Purkinje cells. (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2023spinocerebellarataxiatype pages 1-2)
3. (UGGAA)n RNA folds into abnormal hairpin-like structures with GGA loops leading to nuclear RNA-foci formation; this is demonstrated in human SCA31 Purkinje cells. (zhang2022mechanisticandtherapeutic pages 7-9, zhang2022mechanisticandtherapeutic pages 9-11)
4. The structured RNA leads to binding and altered availability/activity of TDP-43, FUS, and hnRNPA2/B1; whether classical sequestration alone is sufficient for human disease remains incompletely demonstrated. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 7-9)
5. Branch A: disturbed RNA–RNA-binding-protein equilibrium results in RNA-mediated cellular toxicity; fly rescue by RBP co-expression supports causality, but downstream human transcript targets remain insufficiently defined. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 9-11)
6. Branch B: repeat-associated non-AUG translation of (UGGAA)n results in poly-WNGME pentapeptide-repeat protein; this product is detected in patient Purkinje cells and correlates with toxicity in flies. (zhang2022mechanisticandtherapeutic pages 7-9)
7. RNA and translated-product toxicity lead to Golgi fragmentation, ubiquitin-positive degradation granules, abnormal somatic sprouts/synaptic remodeling, Purkinje-cell shrinkage and loss; the exact ordering of these downstream events is partly inferred. (zhang2022mechanisticandtherapeutic pages 5-7)
8. Progressive Purkinje-cell and cerebellar cortical degeneration results in cerebellar atrophy, impaired cerebellar output, gait/limb ataxia, and dysarthria. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 5-7)

Mechanistic detail and evidence strength

Human evidence: RNA foci occur in approximately 30% of examined patient Purkinje cells and measure about 0.2–1.8 μm. Poly-WNGME material has also been detected in affected Purkinje cells. Neuropathology shows Purkinje-cell loss and shrinkage, halo-like amorphous structures containing calbindin-positive somatic sprouts and synaptophysin-positive terminals, ubiquitin-positive granules, and Golgi fragmentation. (zhang2022mechanisticandtherapeutic pages 7-9, zhang2022mechanisticandtherapeutic pages 5-7)

Model evidence: In Drosophila, (TGGAA)80–100/expanded (UGGAA)n expression causes nuclear and cytoplasmic foci, compound-eye degeneration, shortened lifespan, and progressive locomotor defects in a length- and expression-dependent fashion. Co-expression of TDP-43, FUS, or hnRNPA2/B1 reduces toxicity. TDP-43 appears to act as an RNA chaperone, remodeling abnormal UGGAA RNA rather than simply increasing its degradation, and also reduces pentapeptide-repeat synthesis. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 7-9, zhang2022mechanisticandtherapeutic pages 9-11)

Pathways and profiling: No well-validated primary Wnt, MAPK, mTOR, PI3K–AKT, metabolic, immune, or inflammatory pathway has been established for SCA31. Likewise, no mature single-cell, spatial-transcriptomic, patient proteomic, metabolomic, lipidomic, or integrated multi-omic signature was identified. The best-supported biology is repeat-RNA structure, RNA-binding-protein homeostasis, noncanonical translation, protein quality control, Golgi integrity, and neuronal degeneration.

Suggested GO terms: GO:0003723 RNA binding; GO:0016070 RNA metabolic process; GO:0006412 translation; GO:0006914 autophagy only if directly documented in a future dataset; GO:0008219 cell death; GO:0051603 proteolysis involved in cellular protein catabolic process; GO:0007005 mitochondrion organization is not currently supported as a core SCA31 mechanism. Suggested cell ontology: CL:0000121 Purkinje cell, with cerebellar granule neurons and glia not yet established as primary targets.

7. Anatomical structures affected

• Organ/system: central nervous system, principally cerebellum.
• Regional localization: cerebellar cortex and upper vermis; MRI generally shows cerebellar atrophy without substantial brainstem atrophy.
• Cell: Purkinje neurons are the best-established vulnerable population.
• Subcellular compartments: nucleus/RNA foci; cytoplasm for translated pentapeptide material; Golgi apparatus and protein-degradation compartments are pathologically altered.
• Lateralization: bilateral/diffuse rather than unilateral; no consistent asymmetry is established.

Suggested terms include UBERON:0002037 cerebellum, UBERON:0002245 cerebellar vermis, CL:0000121 Purkinje cell, GO:0005634 nucleus, GO:0005794 Golgi apparatus, and GO:0005737 cytoplasm. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 7-9, zhang2022mechanisticandtherapeutic pages 5-7)

8. Temporal development

Onset is insidious and typically late adult/geriatric, averaging roughly 59–64 years. The course is monophasic, chronic, lifelong, and slowly progressive, without spontaneous remission. A natural-history summary reports SARA worsening of approximately 0.8 points/year, wheelchair use near age 79, and death near age 88.5. These are cohort means rather than deterministic predictions for an individual. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 5-7)

Practical stages are: (1) subtle imbalance or dysarthria; (2) clinically evident gait and limb ataxia with retained ambulation; (3) assistive-device dependence; and (4) advanced mobility dependence. These are pragmatic clinical stages, not formally validated SCA31 staging criteria. The long presymptomatic period creates a theoretical intervention window for future allele- or RNA-directed therapies, but no biomarker-defined critical window is established.

9. Inheritance and population

SCA31 is autosomal dominant; each child of a heterozygous affected person has a 50% transmission risk. Penetrance is likely strongly age-dependent, but a precise age-specific penetrance curve was not identified. Expressivity is variable, although the phenotype is usually relatively pure and slowly progressive. An inverse repeat-length/onset relationship exists. Robust genetic anticipation, germline mosaicism rates, de novo frequency, and carrier frequency have not been established. Consanguinity is not a causal factor for this dominant disorder. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 7-9)

SCA31 is described as the third most frequent SCA in Japan in one review, but a reliable population prevalence per 100,000 and annual incidence were not available in the retrieved evidence. It is rare in neighboring Asian groups and absent from large European cohorts; Japanese-ancestry cases abroad reinforce a founder origin. No convincing male:female imbalance is known. (ishikawa2023spinocerebellarataxiatype pages 1-2, zhang2022mechanisticandtherapeutic pages 5-7)

10. Diagnostics

Clinical evaluation

Diagnosis begins with late-onset, slowly progressive, predominantly cerebellar ataxia; a three-generation pedigree and Japanese ancestry increase suspicion. Examination should document gait, stance, limb coordination, speech, ocular motor function, tone, pyramidal/extrapyramidal signs, neuropathy, cognition, swallowing, and falls. Serial SARA scoring is suitable for monitoring.

Brain MRI typically demonstrates cerebellar—often upper vermian—atrophy with relative brainstem sparing. MRI supports localization and excludes acquired mimics but is not molecularly diagnostic. No validated blood, CSF, protein, metabolite, neurofilament, electrophysiological, or liquid-biopsy biomarker is specific to SCA31. Biopsy is not indicated for routine diagnosis. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2)

Genetic testing strategy

1. Order a targeted SCA31 repeat-expansion assay when phenotype/ancestry suggests SCA31, or include it in a comprehensive repeat-expansion ataxia panel.
2. Use locus-specific PCR/fragment methods where technically validated; because the allele is large and compositionally complex, confirmatory Southern blot, long-range PCR, or validated long-read analysis may be required.
3. Standard WES generally performs poorly because the lesion is intronic and much larger than an exome read. A negative WES does not exclude SCA31.
4. Short-read WGS with dedicated repeat-expansion software is more useful than WES but may not fully resolve motif composition. Long-read sequencing can directly characterize complex alleles and interruptions.
5. CMA, karyotyping, FISH, and mitochondrial DNA testing are not first-line assays for the canonical lesion.

Historical discovery used Southern blotting, BAC tiling/shotgun sequencing, and PCR/Sanger analysis. A hybrid sequencing study resolved 2.3–3.1-kb SCA31 alleles at nucleotide resolution in 11 samples. More broadly, 2023 work characterizes repeat-primed PCR and Southern blot as current repeat-expansion diagnostic standards and identifies WGS pipelines as an increasingly practical first step. (ishikawa2023spinocerebellarataxiatype pages 1-2, ishikawa2023spinocerebellarataxiatype pages 2-3)

Differential diagnosis

Important inherited differentials include SCA6 and other late-onset dominant “pure” cerebellar ataxias, SCA5, SCA26, SCA30, SCA36, RFC1-related CANVAS, and episodic ataxias. Acquired and sporadic mimics include multiple-system atrophy–cerebellar type, immune/paraneoplastic ataxia, alcohol or medication toxicity, nutritional deficiencies, thyroid disease, structural lesions, and degenerative idiopathic late-onset cerebellar ataxia. Molecular confirmation distinguishes SCA31 from phenotypically overlapping SCAs.

Cascade testing of adult relatives is appropriate after counseling. Predictive testing of asymptomatic adults should include informed consent and discussion of age-dependent onset, uncertain individual prognosis, psychological effects, insurance/employment issues where relevant, and reproductive choices. Testing asymptomatic minors is generally deferred for an adult-onset condition without proven preventive therapy.

11. Outcome and prognosis

SCA31 produces gradually accumulating neurological disability but appears compatible with survival into advanced age in reported cohorts. Mean wheelchair dependence near 79.4 years and death near 88.5 years suggest that many affected people retain substantial longevity, although these numbers should not be interpreted as controlled life-expectancy estimates. No validated 5- or 10-year survival rates, disease-specific mortality rates, or treatment-stratified survival data were identified. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 5-7)

Major morbidity consists of falls, impaired mobility and activities of daily living, communication difficulty, and advanced dependence. Dysphagia, aspiration, deconditioning, fractures, and social isolation should be monitored as general complications of progressive ataxia, although SCA31-specific rates are unavailable. Recovery of lost cerebellar neurons is not expected; rehabilitation can preserve function and compensate for deficits. Earlier onset/longer alleles and baseline severity may predict greater lifetime disability, but no validated multivariable prognostic calculator or molecular prognostic biomarker exists.

12. Treatment

Current clinical management

There is no approved SCA31-specific disease-modifying pharmacotherapy, gene therapy, cell therapy, ASO, siRNA, or surgical treatment. Care is multidisciplinary:

• physical therapy for balance, gait, strength, aerobic conditioning, falls prevention, and mobility aids;
• occupational therapy and home-safety/adaptive-equipment assessment;
• speech-language therapy for dysarthria and swallowing assessment when indicated;
• nutrition support if intake or swallowing declines;
• management of mood, sleep, pain, spasticity, parkinsonism, or blepharospasm when present;
• avoidance of unnecessary sedating or cerebellotoxic drugs.

Suggested NCIt intervention concepts include Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, Assistive Device, and Supportive Care; exact NCIt identifiers should be release-verified before ingestion.

Experimental strategies

• Enhancing or mimicking the RNA-chaperone actions of TDP-43, FUS, or hnRNPA2/B1 may reduce abnormal UGGAA structure and translation, but systemic manipulation of these pleiotropic proteins could itself be hazardous. (ishikawa2019molecularmechanismsand pages 1-3, ishikawa2023spinocerebellarataxiatype pages 1-2)
• Naphthyridine carbamate dimer (NCD) preferentially binds UGGAA repeats, reduces RNA foci and TDP-43 interaction, and ameliorates fly-eye degeneration. This remains preclinical and has no established human response rate or safety profile. (zhang2022mechanisticandtherapeutic pages 9-11)
• Allele-selective ASOs, RNA degradation, inhibition of repeat-associated translation, and gene editing are rational future approaches but were not demonstrated clinically in the retrieved SCA31 literature.

The clinical-trial search produced no clearly SCA31-specific interventional trial. Trials for recessive TK2 deficiency are mechanistically unrelated and must not be misclassified as SCA31 trials.

13. Prevention

There is no vaccine, medication, lifestyle intervention, environmental remediation, or population screening program that prevents the expansion carrier state.

• Primary prevention: reproductive genetic counseling; where desired and legally available, preimplantation genetic testing or prenatal diagnosis after the familial expansion has been molecularly defined.
• Secondary prevention: cascade/predictive testing in consenting adult relatives and neurological surveillance; this may shorten diagnostic delay but has not been shown to prevent onset.
• Tertiary prevention: falls prevention, exercise and rehabilitation, swallowing surveillance, mobility aids, home modification, and management of complications.
• Newborn screening: not indicated because of late onset, rarity, population restriction, and absence of proven presymptomatic treatment.

14. Other species and natural disease

No naturally occurring SCA31-equivalent disease was identified in companion animals, livestock, or wildlife. The disorder has no infectious transmission or zoonotic potential. Although BEAN1 and TK2 orthologs occur across vertebrates, the pathogenic human repeat configuration and Japanese founder haplotype are the relevant disease features. Species-level NCBI Gene IDs and VBO breed terms were not established in the retrieved material.

15. Model organisms

The best-developed model is transgenic Drosophila melanogaster (NCBI Taxonomy 7227) expressing expanded TGGAA/UGGAA repeats. It recapitulates RNA foci, repeat-length/expression-dependent degeneration, locomotor decline, reduced lifespan, and poly-WNGME production. It has enabled genetic modifier experiments with TDP-43, FUS, and hnRNPA2/B1 and testing of NCD. (ishikawa2019molecularmechanismsand pages 1-3, zhang2022mechanisticandtherapeutic pages 7-9, zhang2022mechanisticandtherapeutic pages 9-11)

Limitations are substantial: fly compound-eye degeneration is not human cerebellar ataxia; transgene overexpression may exceed endogenous levels; repeat context and aging differ from the native human locus; and fly rescue does not establish human efficacy or safety. No well-validated knock-in mouse, rat, zebrafish, patient iPSC-derived Purkinje-cell, cerebellar organoid, or naturally occurring animal model was identified in the retrieved evidence.

Recent developments and evidence gaps

The key recent disease-focused source is Ishikawa’s November 2023 review, which consolidates the Japanese founder genetics, brain-specific bidirectional transcription, Purkinje-cell RNA foci, and RNA-chaperone model (DOI 10.1038/s10038-022-01091-4). Its abstract states that the complex repeat “lies in an intronic segment shared by two genes, BEAN1 … and TK2 … transcribed in mutually opposite directions” and that (UGGAA)n forms “abnormal RNA structures, called RNA foci, in cerebellar Purkinje cell nuclei.” (ishikawa2023spinocerebellarataxiatype pages 2-3, ishikawa2023spinocerebellarataxiatype pages 1-2)

The most relevant 2023–2024 field-wide developments are improved WGS repeat-detection pipelines, increasing clinical use of long-read sequencing for large complex expansions, and continued use of CRISPR-enabled Drosophila models for repeat-disease mechanism and therapeutic screening. These advances improve SCA31 diagnosis and model design but have not yet produced a human disease-modifying therapy.

Critical gaps include precise population prevalence and penetrance, prospective modern natural-history cohorts, validated fluid/imaging biomarkers, native-locus mammalian and human iPSC models, cell-type-resolved omics, direct quantification of RNA versus poly-WNGME contributions in humans, and SCA31-specific interventional trials. Claims about immune activation, mitochondrial dysfunction, epigenetic silencing, environmental modifiers, and systemic disease should therefore be recorded as not established, rather than inferred from other repeat-expansion ataxias.

References

1. (ishikawa2023spinocerebellarataxiatype pages 2-3): Kinya Ishikawa. Spinocerebellar ataxia type 31 (sca31). Journal of Human Genetics, 68:153-156, Nov 2023. URL: https://doi.org/10.1038/s10038-022-01091-4, doi:10.1038/s10038-022-01091-4. This article has 15 citations and is from a peer-reviewed journal.

2. (ishikawa2019molecularmechanismsand pages 1-3): Kinya Ishikawa and Yoshitaka Nagai. Molecular mechanisms and future therapeutics for spinocerebellar ataxia type 31 (sca31). Neurotherapeutics, 16:1106-1114, Oct 2019. URL: https://doi.org/10.1007/s13311-019-00804-6, doi:10.1007/s13311-019-00804-6. This article has 24 citations and is from a peer-reviewed journal.

3. (ishikawa2023spinocerebellarataxiatype pages 1-2): Kinya Ishikawa. Spinocerebellar ataxia type 31 (sca31). Journal of Human Genetics, 68:153-156, Nov 2023. URL: https://doi.org/10.1038/s10038-022-01091-4, doi:10.1038/s10038-022-01091-4. This article has 15 citations and is from a peer-reviewed journal.

4. (zhang2022mechanisticandtherapeutic pages 7-9): Nan Zhang and Tetsuo Ashizawa. Mechanistic and therapeutic insights into ataxic disorders with pentanucleotide expansions. May 2022. URL: https://doi.org/10.3390/cells11091567, doi:10.3390/cells11091567. This article has 15 citations.

5. (OpenTargets Search: spinocerebellar ataxia type 31-BEAN1,TK2): Open Targets Query (spinocerebellar ataxia type 31-BEAN1,TK2, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (zhang2022mechanisticandtherapeutic pages 5-7): Nan Zhang and Tetsuo Ashizawa. Mechanistic and therapeutic insights into ataxic disorders with pentanucleotide expansions. May 2022. URL: https://doi.org/10.3390/cells11091567, doi:10.3390/cells11091567. This article has 15 citations.

7. (zhang2022mechanisticandtherapeutic pages 9-11): Nan Zhang and Tetsuo Ashizawa. Mechanistic and therapeutic insights into ataxic disorders with pentanucleotide expansions. May 2022. URL: https://doi.org/10.3390/cells11091567, doi:10.3390/cells11091567. This article has 15 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0051603 (obsolete proteolysis involved in protein catabolic process) (1 mention) - replaced by GO:0030163

38 of 39 terms resolved to a current term; the rest could not be looked up either way.